Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELEDON PHARMACEUTICALS, INC.

(ELDN)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
2.930 USD   -4.87%
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eledon Pharmaceuticals : Cantor Fitzgerald Starts Eledon Pharmaceuticals at Overweight With $25 Price Target

03/23/2021 | 06:54am EST


ę MT Newswires 2021
All news about ELEDON PHARMACEUTICALS, INC.
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Pr..
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
AQ
01/09Egenesis and Eledon Pharmaceuticals Announces Collaboration for Use of Tegoprubart in P..
CI
2022C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox..
GL
2022C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox..
AQ
2022ELEDON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
2022Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2022Transcript : Eledon Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 202..
CI
More news
Analyst Recommendations on ELEDON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -40,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,12x
Yield 2022 -
Capitalization 40,3 M 40,3 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 1,61x
Nbr of Employees 12
Free-Float 90,2%
Chart ELEDON PHARMACEUTICALS, INC.
Duration : Period :
Eledon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,93 $
Average target price 19,40 $
Spread / Average Target 562%
EPS Revisions
Managers and Directors
David-Alexandre C. Gros Chief Executive Officer & Director
Steven N. Perrin President, Director & Chief Scientific Officer
Paul Little Chief Financial & Accounting Officer
Keith A. Katkin Chairman
Jeffrey D. Bornstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELEDON PHARMACEUTICALS, INC.35.09%40
REGENERON PHARMACEUTICALS, INC.4.12%80 230
VERTEX PHARMACEUTICALS5.19%77 978
WUXI APPTEC CO., LTD.15.80%41 417
BIONTECH SE-3.87%35 092
BEIGENE, LTD.15.96%26 559